Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world. The new products extend the well established HALO® assay platform for hematopoietic stem cells to now include mesenchymal stem cells and induced pluripotent stem cells (iPS) as well. These new high performance assays provide an ability to analyze stem cells for determination of quality, potency and response to toxic agents. Through a previously established alliance, these new products are jointly manufactured by Vitro and HemoGenix®, Inc. Vitro provides its specialized stem cell media and stem cells while HemoGenix® provides the LUMENESC™ and LumiSTEM™ ATP bioluminescent readout reagents and materials.
“Tools for Stem Cell and Drug Development™”
Dr. Ivan Rich, CEO and founder of HemoGenix®, Inc., that was recently featured as a leading provider of cell-based products for drug discovery and development (Drug Discovery & Development, May 1, 2010) said, "We are very pleased to introduce the LUMENESC™-Hu assay for mesenchymal stem cells and LumiSTEM™ for induced pluripotent stem cells. We have developed a regulatory-compliant method for stem cell analysis and look forward to establishing our method as the gold standard for new therapies based on advances in stem cell technology."
HemoGenix and Vitro Diagnostics